Related Experiment Video
Updated: May 11, 2026
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
Telangiectatic osteosarcoma
Jordi Colomina1, Ana Peiro, Laura Trullols
1Department of Oncologic Orthopaedic Surgery, Hospital de Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Spain. jcolomina@gss.scs.es
Purpose:
To review records of 8 patients with telangiectatic osteosarcoma (TOS) and determine whether pathologic fractures correlate with recurrence and survival.
Methods:
Records of 4 men and 4 women aged 17 to 44 (mean, 28) years treated for TOS were reviewed. RESULTS; Of the 8 patients, 4 developed a pathologic fracture and 4 did not. In each group, 2 patients underwent limb salvage surgery and 2 underwent amputation. All patients received neoadjuvant and adjuvant chemotherapy with a combination of at least 2 of the following drugs: doxorubicin, methotrexate, cisplatin, and vincristin. After a mean follow-up of 5.6 (range, 2-16) years, all 4 patients with a pathologic fracture and 2 of the 4 patients without a pathologic fracture were still alive and disease-free. For the remaining patients, one died after 31 months from progression of a lung metastasis, and the other was alive with the disease and had had 2 recurrences, a lung metastasis, and an infection with Klebsiella oxytoca that eventually led to an amputation.
Conclusion:
The presence of a pathologic fracture in patients with TOS was not associated with worse outcome in terms of recurrence and survival.
